Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Bak

Showing results (61-70 of 62) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 62 results.
NPJ Breast Cancer|January 5, 2021
MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefitSanne Løkkegaard, Daniel Elias, Carla L Alves, et al.
Nature Communications|September 3, 2024
An in situ depot for the sustained release of a TLR7/8 agonist in combination with a TGFβ inhibitor promotes anti-tumor immune responsesSophie B Jensen, Ditte E Jæhger, Elizabeth Serrano-Chávez, et al.
Pageof 7

Showing results (61-70 of 62) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 62 results.
NPJ Breast Cancer|January 5, 2021
MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefitSanne Løkkegaard, Daniel Elias, Carla L Alves, et al.
Nature Communications|September 3, 2024
An in situ depot for the sustained release of a TLR7/8 agonist in combination with a TGFβ inhibitor promotes anti-tumor immune responsesSophie B Jensen, Ditte E Jæhger, Elizabeth Serrano-Chávez, et al.
Pageof 7